News from novo nordisk inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 04, 2016, 10:00 ET Saxenda® (liraglutide [rDNA origin] injection) Demonstrated Significant Improvements in Cardiometabolic Risk Factors Over Three Years Compared With Placebo

 Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity – Liraglutide Evidence) Obesity...


Apr 02, 2016, 13:15 ET Victoza® (liraglutide [rDNA origin] injection) Provided Superior HbA1c Reductions in Adults With Type 2 Diabetes Compared to Continued Sitagliptin Treatment

Findings from a clinical trial comparing Victoza® (liraglutide [rDNA origin] injection) and sitagliptin (100 mg), both in combination with...


Apr 02, 2016, 11:45 ET Semaglutide Demonstrated Superior Improvements in Glycemic Control vs Placebo in Adults with Type 2 Diabetes

Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that...


Nov 04, 2015, 12:30 ET Data presented at ObesityWeek showed Saxenda® (liraglutide [rDNA origin] injection) treatment demonstrated significant and sustained weight loss over three years compared with placebo

 Today, new data from the phase 3a SCALE™ (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults)...


Sep 29, 2015, 10:00 ET Novo Nordisk Launches New Medical Resource for People Living with Hemophilia and Other Rare Bleeding Disorders

Novo Nordisk today announced the launch of RareBleedingDisorders.com, a website providing a range of medical information specifically for people in...


May 15, 2015, 12:10 ET New analysis of data in adults with obesity or who are overweight with weight-related comorbidities showed early response to Saxenda® (liraglutide [rDNA origin] injection) predicted greater weight loss

 Today, new data from the phase 3a SCALE™ Obesity and Pre-diabetes trial were presented at the 24th Annual Scientific and Clinical...


Apr 22, 2015, 09:00 ET Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States

Novo Nordisk today announced that Saxenda® (liraglutide [rDNA origin] injection) is now available in the United States. Saxenda® is the...


Mar 07, 2015, 16:00 ET New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® (liraglutide [rDNA origin] injection) showed improvement in blood glucose, CV risk factors and quality of life outcomes

 Today, new data from the phase 3a SCALE™ Obesity and Pre-diabetes trial were presented at The Endocrine Society's 97th Annual Meeting...


Jan 30, 2014, 11:34 ET Novo Nordisk Promotes Eddie Williams to Senior Vice President

Novo Nordisk (NYSE: NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of...